We are Sorry, This Page doesn't Exist
Bristol-Myers says FDA has approved opdivo as treatment for small cell lung cancer
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»
Bristol-Myers wins FDA approval for Opdivo as treatment for small cell lung cancer
Bristol-Myers Squibb Co. said Friday the U.S. Food and Drug Admi.....»»
Bristol-Myers says trial of small cell lung cancer treatment failed to meet main goal
Bristol-Myers Squibb Co. said Friday a late-stage trial of a treatment for small cell lung cancer failed to meet its main .....»»
FDA approves Bristol-Myers combo for metastatic non-small cell lung cancer
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Bristol-Myers" application for AML candidate accepted by FDA for priority review
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Merck Cements Lead in Lung Cancer as Bristol-Myers Fizzles
Merck & Co. might have just shut the door on rival Bristol-Myers Squibb Co. as investors weigh new data that could reshape the treatment of lung cancer, by far the deadliest form of cancer in the U.S......»»
Merck"s Keytruda Gets Priority Review in Difficult Lung Cancer
Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decisio.....»»
Bristol-Myers" Opdivo Gets FDA Nod for Small Cell Lung Cancer
Bristol-Myers' (BMY) blockbuster immuno-oncology drug Opdivo gets the FDA approval for small cell lung cance.....»»
Bristol-Myers Squibb shares decline on failed lung-cancer drug study
Bristol-Myers Squibb Co. shares declined in the extended session Monday after the drug maker said a lung-cancer treatment.....»»
FDA approves Bristol-Myers" Opdivo for initial treatment of gastric cancer
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
NovoCure surges 65% to all-time high on upbeat review of its lung cancer treatment trial
"Pending regulatory approval, the recommended protocol adjustments could accelerate trial completion by more than a year," its CEO said. In this phot.....»»
Bristol-Myers: FDA accepts for Priority Review sBLA for Opdivo combination
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Bristol Myers Squibb"s Opdivo failed a study testing it as a treatment for rare cancer
Shares of B.....»»
Exelixis, Bristol-Myers stocks get a boost from upbeat trial results of a Kidney cancer treatment
Shares of Exelixis Inc. shot up 8.1%, while Bristil-Myers Squibb Co.'s stock slipped 0.3% in premarket trading Monday, .....»»
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off. The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and.....»»
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off. The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news. read more.....»»
Bristol-Myers: Japan"s MHLW approves Opdivo for treatment of esophageal cancer
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Bristol-Myers: FDA accepts for priority review BLA for lisocabtagene maraleucel
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Spectrum Pharmaceuticals shares slide 57% after lung cancer trial misses goals
Shares of biopharmaceutical company Spectrum Pharmaceuticals Inc. slid more than 57% Thursday to mark their worst performance in 17 years, after the company said a mid-stage trial of a treatment for non-small cell lung cancer (NSCLC) missed its main goal......»»
UPDATE: Spectrum Pharma shares slide 47% premarket after trial of lung cancer treatment misses main goal
Spectrum Pharmaceuticals Inc. shares fell 47% in premarket trade Thursday after the company said a mid-stage trial of a treatment for non-small cell lung cancer, or NSCLC, missed its main goal. The Henderson, Nevada-bas.....»»